NCT04417790

Brief Summary

Increased extravascular lung water (EVLW) may increase mortality and morbidity in cardiopulmonary pathology. Many factors can cause increased extravascular lung water and pulmonary edema after cardiac surgery. This includes left ventricular failure, acute mitral regurgitation; systemic inflammatory response post-cardiopulmonary bypass, left to right shunts, transfusion associated acute lung injury, acute respiratory distress syndrome(ARDS) and sepsis. The clinical assessment of lung water ranges from auscultation to radiological methods to invasive measurements like dye dilution or thermodilution studies. Lung ultrasonography is the newest modality for noninvasive assessment of extravascular lung water. Lung ultrasound has been validated against auscultation, chest X-rays, CT chest as well as the bedside gold standard, transpulmonary thermodilution in adults. Critically ill children are more susceptible to complications and worsened outcomes from increased EVLW. Lung ultrasound correlates with clinical and radiological endpoints, but has not been validated against invasive objective measures like transpulmonary thermodilution. Evaluation of transpulmonary thermodilution setups in the pediatric population has shown different normal values and cutoffs compared to adults, possibly due to differential rates growth and development. It is aimed to investigate the correlation of Lung ultrasound based indices of extravascular lung water to invasive measures, assess optimum cutoffs to appropriate clinical endpoints and evaluate their sensitivity and specificity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 10, 2019

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

June 2, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 5, 2020

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2020

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2020

Completed
Last Updated

September 14, 2020

Status Verified

September 1, 2020

Enrollment Period

1 year

First QC Date

June 2, 2020

Last Update Submit

September 11, 2020

Conditions

Keywords

Lung ultrasoundTranspulmonary thermodilution

Outcome Measures

Primary Outcomes (2)

  • correlation of lung USG B-line score with PICCO derived EVLW / EVLWI in pediatric cardiac surgical patients.

    Till extubation or second post-operative day.

  • cutoffs for lung USG B-line score to Predict abnormal EVLWI values.

    Till extubation or second post-operative day.

Secondary Outcomes (1)

  • trending ability of lung USG B-line score to predict PICCO derived EVLW / EVLWI in pediatric cardiac surgical patients.

    Till extubation or second post-operative day.

Study Arms (1)

Study population

Children under 12 years of age, Undergoing elective cardiac surgery for cyanotic or acyanotic congenital heart disease, Aristotle score ≤9, Giving prior written informed consent.

Diagnostic Test: Lung ultrasound and EVLW measurement by transpulmonary thermodilution.

Interventions

Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement

Study population

Eligibility Criteria

Age1 Year - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Children with cyanotic or acyanotic heart undergoing elective cardiac surgery.

You may qualify if:

  • aged under 12 years,
  • undergoing elective cardiac surgery for cyanotic or acyanotic congenital heart disease,
  • Aristotle score ≤9,
  • with prior written informed consent

You may not qualify if:

  • Neonates,
  • Children with any chest wall deformity,
  • children with known lung disease, active infection,
  • those weighing less than 3.5 kg.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Postgraduate Institute of Medical Education & Research

Chandigarh, 160012, India

Location

MeSH Terms

Conditions

Heart Defects, CongenitalPostoperative Complications

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Bhupesh Kumar, DM

    Post Graduate Institute of Medical Education and Research, Chandigarh

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Fellow, Cardiac Anaesthesia

Study Record Dates

First Submitted

June 2, 2020

First Posted

June 5, 2020

Study Start

August 10, 2019

Primary Completion

August 15, 2020

Study Completion

August 30, 2020

Last Updated

September 14, 2020

Record last verified: 2020-09

Locations